Circulating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK–Wip1 Signaling

20260 citationsJournal Articlegold Open Access

Authors

Jiayao Zhang · Nankai University

Mingqing Zhang · Nankai University

Xiaojing Wu · Nankai University

Haoren Jing · Nankai University

Peiran Li · Humane Society of the United States

Wei Wang · Nankai University

Xi Guo · Nankai University

Abstract

Butyrate reduces cetuximab efficacy in KRAS wild-type colorectal cancer through EGFR and AMPK-Wip1 signaling, and may represent a candidate predictive biomarker for treatment response.

Topics & Keywords

Cancer, Hypoxia, and Metabolism Immune cells in cancer Cancer Research and Treatments

Publication Details

Published in: Drug Design Development and Therapy

Volume Volume 20, pp. 1-16

DOI: 10.2147/dddt.s574116

Field-Weighted Citation Impact: 0.00

Command Palette

Circulating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK–Wip1 Signaling

Authors

Abstract

Topics & Keywords

Publication Details